Caligiuri M P, Rockwell E, Jeste D V
Department of Psychiatry, University of California, San Diego, USA.
Am J Geriatr Psychiatry. 1998 Winter;6(1):75-82.
The authors examined whether the presence of extrapyramidal side effects (EPS), measured before neuroleptic treatment was initiated, could be used to predict the development and severity of neuroleptic-induced parkinsonism (NIP) in Alzheimer's disease (AD). Twenty-four newly medicated probable AD patients were assessed with a battery of measures of extrapyramidal motor function. Assessments were made before neuroleptic therapy, and 3 and 9 months after treatment. Posttreatment clinical findings revealed that 66.7% of the AD patients developed NIP. Patients who developed NIP exhibited more severe pretreatment bradykinesia on instrument-derived measures. These findings suggest that a substantial proportion of AD patients treated with neuroleptics develop significant EPS and that the risk for EPS can be estimated before intervention by use of instruments measuring motor function.
作者们研究了在开始使用抗精神病药物治疗前测量的锥体外系副作用（EPS）的存在情况，是否可用于预测阿尔茨海默病（AD）患者中抗精神病药物诱发的帕金森症（NIP）的发生和严重程度。对24例新接受药物治疗的可能患有AD的患者进行了一系列锥体外系运动功能测量。在抗精神病药物治疗前、治疗后3个月和9个月进行评估。治疗后的临床结果显示，66.7%的AD患者出现了NIP。出现NIP的患者在仪器测量的指标上表现出更严重的治疗前运动迟缓。这些发现表明，相当一部分接受抗精神病药物治疗的AD患者会出现明显的EPS，并且在干预前通过使用测量运动功能的仪器可以估计EPS的风险。
